36 results about "Dispersible tablet" patented technology

The invention discloses a dotenorad tablet and a preparation method thereof, belongs to the technical field of medicine preparation, and is used for solving the technical problem that the dissolution rate and the disintegration rate of the dotenorad tablet in the prior art need to be further improved. A preparation method of a dotenorad tablet comprises the following steps: carrying out ball milling on a dispersion liquid by using a planetary ball mill, and carrying out post-treatment to obtain a dotenorad nanocrystal, the Gemini type modified surfactant, the modified chitosan oligosaccharide and the modified xanthan gum are cooperatively introduced, stable dispersion of nanocrystals, uniform forming of a tablet structure and efficient control of a sustained-release coating are achieved, the three components perform their own functions, a stable and controllable drug release system is constructed, the dissolution rate, content uniformity and storage stability of the preparation are effectively improved, and the sustained-release effect of the tablet is improved. And the technical bottlenecks of poor dispersibility, unstable release and the like of the traditional preparation dotenorad tablet are broken through.

The present invention relates to an orodispersible tablet manufactured by a direct compression method comprising Topiramate or pharmaceutically acceptable salts thereof, at least one or more diluents, at least two or more disintegrant, at least one lubricant, at least one glidant, and at least one flavoring agents. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said Orodispersible tablet.

The invention discloses a Shenshuaining dispersible tablet and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The Shenshuaining dispersible tablet provided by the invention has the advantages of being convenient to carry and take and accurate in dosage, is excellent in moisture resistance, is quick to disintegrate, is excellent in dispersion state and is quick to dissolve out, and the bioavailability of the Shenshuaining dispersible tablet is improved. The key points of the technical scheme are as follows: by selecting specific types and dosages of a filling agent, a disintegrating agent and a lubricating agent, the consistency and reliability of the medicine quality are ensured, the disintegration is rapid, the dispersion state is good, the dissolution is rapid, and the dissolution and moisture resistance of effective components of the medicine are greatly improved.

The invention relates to the technical field of nutritional supplement preparations for pets, in particular to a high-activity non-denatured II-type collagen pet joint dispersible tablet and a preparation method thereof. According to the technical scheme, the soft capsule is prepared from the following raw materials in percentage by weight: 4.0%-7.0% of non-modified II type collagen, 4.0%-6.0% of sodium chondroitin sulfate, 4.0%-6.0% of green lip mussel powder, 0.5%-1.5% of sodium hyaluronate, 30%-40% of microcrystalline cellulose, 12%-18% of sodium carboxymethyl starch, 15%-22% of sweet potato starch, 4.0%-6.0% of polyvinylpolypyrrolidone, 6.0%-10.0% of enzymolysis chicken liver powder, 2.0%-4.0% of yeast extract, 1.5%-3.5% of lactose goat milk powder and 0.3%-0.7% of magnesium stearate. A core active component structure is protected by virtue of nano embedding and a whole-course low-temperature process, and a dual joint maintenance path of immunoregulation and nutrition supplement is constructed.

The present invention relates to an orodispersible tablet manufactured by a wet granulation method comprising Famotidine or pharmaceutically acceptable salts thereof, one or more diluents, at least on

An orodispersible tablet of topiramate with masked bitter taste, comprising: topiramate or pharmaceutically acceptable salt(s) thereof at 20-40 %w / w; a diluent at 35-80 %w / w (e.g., microcrystalline ce

The present invention relates to a solid pharmaceutical composition manufactured by a wet granulation method comprising carbidopa and levodopa or pharmaceutically acceptable salts thereof, one or more disintegrant, one or more diluent, at least one binder, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The invention provides a torasemide dispersible tablet as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations, the torasemide dispersible tablet comprises the following components: torasemide, microcrystalline cellulose, lactose, pregelatinized starch, cross-linked sodium carboxymethyl cellulose and magnesium stearate, the technical problem that a patient is difficult to swallow is solved, and the torasemide dispersible tablet is suitable for clinical application. The technical effects of high stability, rapid disintegration and high dissolution rate are achieved. The torasemide dispersible tablet is stable, easy to swallow, high in disintegration speed after entering a human body and high in bioavailability.

1. Name of the product in this design: Packaging Box (Cefdinir Dispersible Tablets 2). 2. Purpose of this design: Product packaging. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key points: the front view. 5. The design for which protection is sought includes color.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a radix gentianae liver-purging solid dispersible tablet and a preparation method thereof. The radix gentianae liver-purging solid dispersible tablet is prepared from the following components in parts by weight: 20 to 40 parts of radix gentianae liver-purging thick paste, 0.4 to 0.6 part of radix bupleuri-radix angelicae sinensis volatile oil, 31 to 56 parts of a water-soluble polymer dispersion carrier, 0.8 to 2.4 parts of an inclusion agent, 8 to 16 parts of a disintegrating agent, 18 to 31 parts of a diluent, 7 to 18 parts of an adhesive, 0.5 to 2 parts of a flow aid and 0.3 to 0.8 part of a lubricating agent, the radix gentianae liver-purging solid dispersible tablet provided by the invention can be quickly disintegrated and released, quickly exerts a treatment effect, corrects a damp-heat state of liver and gallbladder, and quickly improves clinical symptoms of damp-heat of liver and gallbladder, dizziness, hot eyes, tinnitus, deafness, hypochondriac pain, bitter taste in the mouth, red and astringent urine and damp-heat leukorrheal.

This invention provides a controllable tableting device for nabumetone dispersible tablets and the resulting nabumetone dispersible tablets, belonging to the field of pharmaceutical processing equipment. It includes a feed shell and vertical tubes. The feed shell is annularly arranged with several vertical tubes evenly distributed and fixedly connected to its bottom surface. Each vertical tube contains a feed assembly. A collection shell is installed on the lower side of each vertical tube. The lower sides of several collection shells are movably connected to the same circular shell, and a fixing plate is fixedly connected to the side wall of the collection shell. This invention uses an electric push rod to drive the annular plate, which in turn drives a movable plate via a connecting plate. The movable plate, in turn, drives a first push plate via a circular rod, extending the first push plate to a suitable length within the circular shell. When the collection shell rotates, the first push plate controls the movement length of the movable rod, thereby controlling the tableting specifications of the nabumetone dispersible tablets to meet the needs of producing different specifications of nabumetone dispersible tablets.

An orodispersible solid pharmaceutical composition in tablet form is disclosed comprising a) carbidopa and levodopa or pharmaceutically acceptable salts thereof, b) one or more diluent, c) one or more

This invention provides a PND cyclodextrin inclusion complex, its preparation method, and its applications, relating to the field of pharmaceutical formulation technology. The method for preparing the PND cyclodextrin inclusion complex of this invention does not use organic solvents, is simple and easy to control, and has low cost. The technical solution of this invention greatly improves the solubility of PND in water, enhances the therapeutic effect of PND, and improves the stability of PND. This inclusion complex is suitable for preparing clinically required solid and liquid dosage forms, including infusions, injections, powder injections, oral solutions, novel nasal drops, nasal sprays, syrups, tablets, capsules, granules, and dispersible tablets. This inclusion complex can be used to prepare drugs for the prevention and treatment of influenza A virus infection.

The present disclosure relates to a dispersible tablet capable of disintegrating in very small volumes of water rapidly (e.g. within a period of 3 minutes) to form a suspension that is free flowing and has an acceptable mouthfeel. A dispersible tablet of daprodustat and medical uses of this tablet are also disclosed.

1. Name of the product in this design: Packaging Box (Cefdinir Dispersible Tablets 3). 2. Purpose of this design: Product packaging. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key features: the front view. 5. The design for which protection is sought includes color.

The present disclosure relates to a method for preparation of a lisdexamfetamine dimesylate dispersible tablet. The method for preparation comprises: dry mixing lisdexamfetamine dimesylate, a diluent, a binder and an anti-static agent to form a dry mix blend; intermediate granular blending of a filler, a cushioning agent, a disintegrating agent, and a sweetener to form an intermediate granular blend; adding and blending the dry mix blend and the intermediate granular blend to form an intermediate drug blend; lubricating the intermediate drug blend with a lubricant to form ready to compress drug granules; and compressing the ready to compress drug granules to form a lisdexamfetamine dimesylate dispersible tablet.

This invention discloses an azithromycin dispersible tablet preparation system, including a fixed platform, a sliding platform slidably connected to the upper end of the fixed platform, guide rails fixed on the front and rear sides of the left side of the upper end of the sliding platform, and a tableting mold fixed on the upper side between the guide rails. The tableting mold has a mold hole on its upper side. By moving the sliding plate below the tableting mold, the sliding plate can provide support during the tableting of powdered azithromycin. After tableting, the screw is driven by a screw motor to rotate, and the screw is threadedly connected to the sliding plate, causing the sliding plate to move to the right away from directly under the tableting mold. Then, the hydraulic cylinder moves the tableting plate down, pushing the formed azithromycin dispersible tablet onto the sliding platform. Then, the sliding plate moves to the left and slides under the tableting mold, which pushes the azithromycin dispersible tablet on the sliding platform to the right away from directly under the tableting mold. This eliminates the need for manual removal of the formed azithromycin dispersible tablet, saving manpower.

The utility model discloses a cerebroprotein hydrolysate dispersible tablet forming auxiliary device, and relates to the field of dispersible tablet forming auxiliary devices, the cerebroprotein hydrolysate dispersible tablet forming auxiliary device comprises a workbench and a mounting rack, the top of the workbench is fixedly provided with a fixed support, and the top of the fixed support is symmetrically provided with stamping cylinders; and the extending end of the stamping air cylinder is fixedly connected with a tablet pressing assembly. According to the cerebroprotein hydrolysate dispersible tablet forming auxiliary device, through arrangement of a connecting plate, a mounting frame can drive the connecting plate to ascend and descend during operation, so that the connecting plate drives a fixing plate to move upwards; furthermore, an ejector rod moves along the interior of a guide hole to drive an ejector plate to eject the pressed dispersible tablets out of the interior of a medicament bearing box, so that the aim of conveniently taking materials is fulfilled; therefore, the situation that the processing efficiency of a worker is interfered due to the fact that the worker needs to spend a long time to take out the pressed and formed tablets from the mold is avoided.

The invention pertains to dispersible tablets comprising as active ingredient N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1, 1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, methanesulfonate salt, processes for preparing the same, and processes for using the same.

The invention provides controllable tabletting equipment for nabumetone dispersible tablets and the prepared nabumetone dispersible tablets, and belongs to the field of medicine processing equipment. Comprising a feeding shell and vertical pipes, the feeding shell is annularly arranged, the multiple vertical pipes are evenly distributed and fixedly connected to the bottom face of the feeding shell, feeding assemblies are arranged in the vertical pipes, a material collecting shell is installed on the lower side of each vertical pipe, and the lower sides of the multiple material collecting shells are movably connected with the same round shell; and the side wall of the material collecting shell is fixedly connected with a fixed plate. An electric push rod drives an annular plate to move, the annular plate drives a movable plate to move through a connecting plate, the movable plate drives a first push plate to move through a round rod, so that the first push plate extends into a round shell by a proper length, and when a material collecting shell rotates, the movement length of a movable rod is controlled through the first push plate; therefore, the tabletting specification of the nabumetone dispersible tablet can be controlled, and the requirement of actually producing nabumetone dispersible tablets with different specifications can be met.

The present invention relates to a solid pharmaceutical composition manufactured by a wet granulation method comprising levetiracetam or pharmaceutically acceptable salts thereof, at least one or more disintegrant, at least one or more diluent, at least one binder, at least one glidant, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The invention discloses a compound artemether dispersible tablet and a preparation method thereof. The compound artemether dispersible tablet is prepared from the following components in parts by mass: 20 parts of artemether, 120 parts of benflumetol, 120 to 160 parts of filler, 20 to 30 parts of disintegrating agent, 5 to 15 parts of adhesive, 15 parts of lubricant and 0.5 to 2 parts of surfactant, the disintegrating agent is at least one of croscarmellose sodium, carboxymethyl starch sodium and low-substituted hydroxypropyl cellulose. According to the invention, by adopting a double disintegrating agent system (cross-linked sodium carboxymethyl cellulose and carboxymethyl starch sodium) and a surfactant (lauryl sodium sulfate), the disintegration performance and stability of the product are obviously improved, and the adopted wet mixing granulation process is simple and easy to realize industrial production; in the obtained dispersible tablet, the dissolution rate of artemether within 3 hours reaches 85% or above. The product has the advantages of rapid disintegration, good stability and the like, and is suitable for children, old people and patients with dysphagia.

The present application relates to the technical field of pharmaceutical preparation, and in particular to a preparation method of amoxicillin dispersible tablets, comprising the following steps: S1, mixing based on an internal complex cross-linking disintegrant system to form an internal water absorption channel structure, and obtaining first mixed material; S2, granulating after adjusting granulation parameters based on the bulk density and first angle of repose of the first mixed material, and obtaining first mixed granules; S3, mixing based on an external complex cross-linking disintegrant system to form a granule inter-disintegration network structure, and obtaining second mixed material; and S4, tabletting after adjusting the tabletting pressure based on the second angle of repose of the second mixed material and the particle size distribution of the first mixed granules. The present application significantly improves the disintegration performance, dissolution rate and quality stability of the amoxicillin dispersible tablets by constructing intelligent process control logic.

The invention relates to the technical field of biological medicine, and discloses a pharmaceutical composition for treating drug-induced liver injury and a preparation method thereof, active ingredients are ginsenoside Re and betaine, and the active ingredients are matched with pharmaceutically acceptable auxiliary materials such as microcrystalline cellulose to prepare dispersible tablets. The processes of gradient drying, precise tabletting and the like are adopted for preparation, and the component mixing and dissolution efficiency is optimized. The composition can significantly reduce transaminase and repair liver injury through the synergistic effect of oxidation resistance, inflammation resistance and hepatocyte repair, has the effect superior to that of a pharmaceutical composition with a single active component, and is fast in disintegration, high in dissolution rate, good in safety, controllable in quality and suitable for industrial production.

The invention relates to a preparation method of a ridexamphetamine dimesylate dispersible tablet. The preparation method comprises the following steps: carrying out dry mixing on ridexamphetamine dimesylate, a diluent, an adhesive and an antistatic agent to form a dry-mixed blend; performing intermediate particulate blending on a filler, a buffer, a disintegrant, and a sweetener to form an intermediate particulate blend; adding and blending the dry blend and the intermediate particulate blend to form an intermediate pharmaceutical blend; lubricating the intermediate drug blend with a lubricant to form standby compressed drug particles; and compressing the standby compressed medicine particles to form the ridexamphetamine dimesylate dispersible tablet.

The present invention relates to an orodispersible tablet manufactured by a wet granulation method comprising Famotidine or pharmaceutically acceptable salts thereof, one or more diluents, at least one disintegrant, at least one lubricant, at least one binder, at least one sweetener, at least one flavoring agents and at least one vehicle. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said orodispersible tablet.

The invention relates to the technical field of biological medicine, in particular to nateglinide solid dispersible tablets and a preparation method thereof. According to the solid dispersible tablet disclosed by the invention, the solubility, the dissolution rate and the bioavailability of the nateglinide medicine are remarkably improved, the blood concentration of the nateglinide medicine is improved, the action time of the medicine is prolonged, and the defect that the action time of the nateglinide is short is overcome. Compared with a common dispersible tablet, the nateglinide solid dispersible tablet disclosed by the invention can realize the same or even better clinical curative effect under the condition of reducing the dosage, and the probability of adverse reaction is reduced. The nateglinide solid dispersible tablet is obtained through mixing granulation and tabletting, the preparation process is simple and convenient, the solubility and the release rate of nateglinide can be greatly improved, and the bioavailability of drugs is improved; meanwhile, the content of nateglinide can be accurately controlled, so that the prepared nateglinide solid dispersible tablet has better intra-batch and inter-batch content uniformity, and the stability of clinical curative effect and the safety of clinical use are improved.

1. The name of the design product: packaging box (entecavir dispersible tablets). 2. The use of the design product: for product packaging. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective view 1.

An orodispersible tablet of levetiracetam, comprising: 55-85 %w / w levetiracetam or pharmaceutically acceptable salts thereof; a diluent at 2-35 %w / w (e.g. microcrystalline cellulose (MCC) (1-20 %w / w),